Johnson & Johnson upbeat on its R&D pipeline, inc expanding indications

Early-stage compounds and new filings targeted in five therapeutic areas, as well as expanding indications for strong core products to  build its pipeline in a product, were among the topics focused upon by  US drug major Johnson & Johnson in a recent presentation to  pharmaceutical sector analysts

Having just announced a $1.0-billion acquisition of fellow-USA-based  Cougar Biotechnology in order to bolster its oncology offerings  (Marketletter June 1), J&J has now reviewed the growth strategies and  pipeline for its pharmaceutical business at a meeting with the  investment community. Senior leaders from the company's pharmaceutical  segment outlined how continued expansion of its core products, progress  in its pipeline, and an end-to-end approach to its R&D will fuel the  group's long-term growth and address unmet medical needs.